Combination of the digital therapeutic glucura with intermittent continuous glucose monitoring (CGM) significantly improved HbA1c reduction compared to CGM with standard care alone in non-insulin-treated type 2 diabetes.
Glucura users achieved higher rates of stringent glycaemic targets (HbA1c <7.0% and <6.5%) and experienced greater weight loss.
Beyond metabolic benefits, glucura improved mental health and reduced diabetes-related distress without serious adverse events.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
